AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02768376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Induction by propofl 1.5-2 mg/kg, Fentanyl 1-2 mic/kg and atracrium 0.5 mg/kg Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
Study NCT02647151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METHYLAMINOLEVULINATE HYDROCHLORIDE
Description: This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed.
Study NCT02647151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: METHYLAMINOLEVULINATE HYDROCHLORIDE
Description: This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed.
Study NCT02647151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMINOLEVULINIC ACID HYDROCHLORIDE
Description: This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed.
Study NCT02647151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMINOLEVULINIC ACID HYDROCHLORIDE
Description: This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed.
Study NCT02162888 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Test Product (Bendamustine)
Study NCT02221089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escherichia coli Endotoxin
Description: dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
Study NCT02221089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escherichia coli Endotoxin
Description: dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
Study NCT02221089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Retaron®
Description: Dosage 1 capsule Retaron® per day.: Lutein 10mg, Zeaxanthin 2mg, Fishoil 500mg (with 250 mg DHA, 30 mg EPA), Vitamin C 100mg, Zinc 10mg, Selen 25µg, Vitamin E 25mg, Taurin 50mg, Aroniaextract 50mg, administered for 14 days
Study NCT02221089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical in appearance to Retaron capsules
Study NCT04378166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart glass
Description: Practitioner wears smart glasses connected to ultrasound machine during central venous catheterization
Study NCT02433977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conjugated Linolenic Acid
Description: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day
Study NCT02433977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
Study NCT02276027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.
Study NCT02276027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.
Study NCT02433977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrate
Description: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
Study NCT02603796 — intervention group
Intervention type: OTHER
Intervention: 3D Scan of nares
Description: 3D scan of subjects nose prior to implementation of ncpap and upon discontinuation of ncpap.
Study NCT00170001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: 40 mg bid dosing
Study NCT00170001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: 40 mg BID
Study NCT00791076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2pmol/kg-1/min-1 placebo infused continuously over 72 hours.
Study NCT00791076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic Polypeptide (PP)
Description: 2pmol/kg-1/min-1 PP infused continuously over 72 hours.
Study NCT04023929 — intervention group
Intervention type: PROCEDURE
Intervention: Cord blood sampling
Description: A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
Study NCT02361476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Injection - during surgery
Study NCT02361476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection - during surgery
Study NCT01857596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion, Lorexys low-dose, Lorexys moderate-dose
Description: Lorexys is a proprietary fixed-dose combination of two agents
Study NCT00813969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cell transplantation
Description: A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion
Study NCT03390101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085 Q2W
Description: In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54.
Study NCT03390101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085 Q4W
Description: In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54.
Study NCT03390101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54.
Study NCT04259723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR during TAVI
Description: Virtual Reality (VR) glasses
Study NCT03487692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes MESSAGES Program
Description: Health centers in the 2018 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
Study NCT03487692 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diabetes MESSAGES Program (second trial)
Description: During the first trial period, health centers in the 2020 Training Cohort will collect data on patients receiving usual care. After the first trial period, health centers in the 2020 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
Study NCT06200142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Untargeted metabolomics
Description: Untargeted metabolomics in bloodspots and in plasma
Study NCT06200142 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: WES and WGS
Description: WES reanalysis and WGS analysis
Study NCT00830791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941 20 mg
Description: Two 10-mg tablets of MK-0941 administered as a single oral dose.
Study NCT00830791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941 5 mg
Description: MK-0941 administered as one single 5-mg tablet.
Study NCT02878356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular MI-training
Description: Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
Study NCT02878356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular MI-training + supervision half
Description: Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
Study NCT02878356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular MI-training + supervision full
Description: Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
Study NCT00617669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: intravenous infusion given every three weeks
Study NCT00617669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous infusion given every three weeks
Study NCT00617669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 10 mg oral once daily dose
Study NCT00617669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo oral tablet once daily
Study NCT00297024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
Study NCT04367571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative treatment (OMT)
Description: OMT techniques were focused on correcting the dysfunctions found before each OMT session and included myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field.~OMT group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3).
Study NCT04367571 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Manual Placebo (MP)
Description: The MP treatment consists of passive touch without joint mobilization in a protocolled order. The practictioners will be standing next to the bed, they'll touch lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they'll touch for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest for 5 minutes each.~MP group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3).
Study NCT03938753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audéo M90-T
Description: Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
Study NCT03121651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RL-adaptive application
Description: Up to 6 dyads of individuals with disabilities and their caregivers will be recruited to collaborate in defining the features and content of the RL-adaptive support. The steps in developing the RL-adaptive support include having the dyads use for approximately 6 weeks each:~1. young adult uses an electronic medication pillbox that sends its pillbox openings within one hour of opening to the research team,~2. young adult uses the electronic medication pillbox + both use a commercially available medication reminder app + caregiver uses a pillbox opening notification app, and~3. young adult uses the electronic medication pillbox + the RL-adaptive support including push notifications in the form of text messages + caregiver uses the pillbox opening notification app.~The goal is to reduce the number of caregiver prompts necessary for the medication pillbox to be opened.
Study NCT02697110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Edutainment based intervention
Description: Edutainment intervention package
Study NCT04013243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
Study NCT04013243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
Study NCT01109056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine ophthalmic emulsion 0.05%
Description: One drop in the study eye (or eyes) administered four times daily (QID)
Study NCT01109056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: One drop in the study eye (or eyes) administered four times daily (QID)
Study NCT02052414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin ER
Description: Patient who are on gralise will report efficacy by rating his or her pain rating on a digital pain scale (11 points) from 0 to 10 on each scheduled clinical visits, which will be compared to their pain level at baseline.~In addition, patients will also record the doses and any adverse effects that might arise during the trial in a diary provided by the study. All information will be recorded in a paper diary that will be followed by coordinator during each follow up visits.
Study NCT00716833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxibe
Description: Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.
Study NCT00716833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).
Study NCT04397666 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: conjunctival RT PCR
Description: conjunctival sample in covid-19 patients
Study NCT01670578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Study NCT01670578 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Study NCT02355873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AN69ST hemofilter
Study NCT02355873 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AN69 hemofilter
Study NCT02480036 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IORT with Kyphoplasty
Description: IORT with kyphoplasty is give concurrently for the treatment of spinal metastases
Study NCT02480036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrabeam®
Study NCT04140760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symprove
Description: A liquid probiotic
Study NCT04140760 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Symprove placebo product
Description: An inert placebo
Study NCT01491438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary
Description: PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)during 12 weeks.~Types of dressing: enzyme cutting dressing (collagenase), hydrogel, polymeric foam, alginate dressing, hydrocolloid hydrofiber dressing, silver dressing, coal and silver dressing, argentum sulfadiazine dressing, polyurethane or caster hydrocolloid dressing
Study NCT01491438 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary
Description: Twice a week (days 1 and 4) during 12 weeks
Study NCT02527200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
Study NCT02527200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
Study NCT04647981 — intervention group
Intervention type: OTHER
Intervention: Xpert® Bladder Cancer Monitor Test
Description: The urine sample is analyzed with the Xpert® Bladder Cancer Monitor test.
Study NCT03196700 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with metastatic or locally advanced head and neck cancer.
Study NCT04124497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: * Daratumumab 16 mg/kg intravenously at following schedule:~* cycle 1 and 2: days 1, 8, 15, and 22~* cycle 3 through 6: days 1, and 15~* from cycle 7 until disease progression: day 1.
Study NCT04124497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg once daily on days 1-21
Study NCT04124497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (>75 years old) on days 1, 8, 15 and 22
Study NCT02744820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GMC-252-L-Lysine Salt
Description: 1 dose by oral route, once a day, 28 days
Study NCT01165840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone
Description: 100 mg PO x 1 dose
Study NCT03862651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor is an intravenous analog of adenosine triphospate with a potent, selective and specific affinity for P2Y12 receptors.